Nascholing.net: de open leeromgeving voor arts en apotheker Inloggen | Aanmelden 
Home | Cursussen | Bestellen | Mijn pagina | Contact | FAQ
Zoeken    


 RLS
 FTO-werkboek
A.  KLINIEK VAN RLS
 
B.  OORZAKEN VAN RLS
 
C.  DIAGNOSE RLS
 
D.  NIET-MEDICAMENTEUZE BEHANDELING
 
E.  MEDICAMENTEUZE BEHANDELING
 
F.  LITERATUUR


     
 Conclusie   

F. LITERATUUR

  1. Wellbery CE. Getting the facts on restless legs. Am Fam Physician 2000; 62(1):51-2.
  2. Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med 2003; 348(21):2103-9.
  3. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001; 18(2):128-47.
  4. Ekbom K-A. Restless legs. Acta Med Scand 1945; 158(Suppl):1-123.
  5. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5(3):237-46.
  6. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165(11):1286-92.
  7. Walters AS, Hickey K, Maltzman J, Verrico T, Joseph D, Hening W et al. A questionnaire study of 138 patients with restless legs syndrome: the "Night-Walkers"survey. Neurology 1996; 46(1):92-5.
  8. Silber MH. Restless legs syndrome. Mayo Clin Proc 1997; 72:261-4.
  9. Earley CJ. Restless Legs Syndrome. N Engl J Med 2003; 348(21):2103-9.
  10. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism : prevalence and association among canadians. Sleep 1994; 17(8):739-43.
  11. Comella CL. Restless legs syndrome : treatment with dopaminergic agents. Neurology 2002; 58(Suppl 1):S87-S92.  [ABSTRACT]
  12. Lichstein KL, Durrence HH, Taylor DJ, Bush AJ, Riedel BW. Quantitative criteria for insomnia. Behav Res Ther 2003; 41(4):427-45.
  13. Knuistingh Neven A, Lucassen PLBJ, Bonsema K, et al. NHG-Standaard Slaapproblemen en slaapmiddelen. Huisarts Wet 2005; 48(8):402-15.  [FULL TEXT]
  14. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160(14):2137-41.
  15. Rijsman R, Neven AK, Graffelman W, Kemp B, de Weerd A. Epidemiology of restless legs in The Netherlands. Eur J Neurol 2004; 11(9):607-11.
  16. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000; 54(5):1064-8.  [ABSTRACT]
  17. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999; 22(7):970-99.
  18. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002; 53(1):547-54.
  19. Lee KA, Zaffke ME, Baratte-Beebe K. Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron. J Womens Health Gend Based Med 2001; 10(4):335-41.
  20. O'Keeffe ST. Restless legs syndrome. Arch Intern Med 1996; 156:243-8.
  21. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998; 21(4):371-7.
  22. Walters AS, Picchietti DL, Ehrenberg BL, Wagner ML. Restless legs syndrome in childhood and adolescence. Pediatr Neurol 1994; 11(3):241-5.
  23. Restless legs syndrome: detection and management in primary care. National Heart, Lung, and Blood Institute Working Group on Restless Legs Syndrome. Am Fam Physician 2000; 62(1):108-14.
  24. Winkelmann J, Stautner A, Samtleben W, Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002; 17(5):1072-6.
  25. Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology 1999; 52(5):907-10.
  26. Evidente VGH, Adler CH. How to help patients with restless legs syndrome: discerning the indescribable and relaxing the restless. Postgrad Med J 2006;(105):59-61.
  27. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000; 55(9):1404-6.  [ABSTRACT]
  28. Sowers JR, Vlachakis N. Circadian variation in plasma dopamine levels in man. J Endocrinol Invest 1984; 7(4):341-5.
  29. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982; 39(11):739.
  30. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study. Neurology 2003; 60(4):601-5.  [ABSTRACT]
  31. Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54(2):502-4.  [ABSTRACT]
  32. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002; 249(2):164-70.
  33. Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16(6):1105-9.
  34. Montplaisir J, Lorrain D, Godbout R. Restless legs syndrome and periodic leg movements in sleep: the primary role of dopaminergic mechanism. Eur Neurol 1991; 31(1):41-3.
  35. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4(2):101-19.
  36. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995; 10(5):634-42.
  37. Winkelmann J, Muller-Myhsok B, Wittchen HU, Hock B, Prager M, Pfister H et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002; 52(3):297-302.
  38. Lutz EG. Restless legs, anxiety and caffeinism. J Clin Psychiatry 1978; 39(9):693-8.
  39. Lavigne GL, Lobbezoo F, Rompre PH, Nielsen TA, Montplaisir J. Cigarette smoking as a risk factor or an exacerbating factor for restless legs syndrome and sleep bruxism. Sleep 1997; 20(4):290-3.
  40. Lazzarini A, Walters AS, Hickey K, Coccagna G, Lugaresi E, Ehrenberg BL et al. Studies of penetrance and anticipation in five autosomal-dominant restless legs syndrome pedigrees. Mov Disord 1999; 14(1):111-6.
  41. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4(2):121-132.
  42. Shneerson J. Management of insomnia. Update 2006;(12):38-42.
  43. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 38(12):1845-8.  [ABSTRACT]
  44. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993; 16(8):717-23.
  45. Montplaisir J, Godbout R, Poirier G, Bedard MA. Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa. Clin Neuropharmacol 1986; 9(5):456-63.
  46. Trenkwalder C, Stiasny K, Pollmacher T, Wetter T, Schwarz J, Kohnen R et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995; 18(8):681-8.
  47. Staedt J, Hunerjager H, Ruther E, Stoppe G. Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication. J Neural Transm 1998; 105(2-3):265-8.
  48. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002; 3 Suppl:S23-5.
  49. Trenkwalder C, Hundemer HP, Lledo A, Swieca J, Polo O, Wetter TC et al. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004; 62(8):1391-7.  [ABSTRACT]
  50. Silber MH, Shepard JW, Jr., Wisbey JA. Pergolide in the management of restless legs syndrome: an extended study. Sleep 1997; 20(10):878-82.
  51. Stiasny K, Robbecke J, Schuler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial. Sleep 2000; 23(3):349-54.
  52. Wetter TC, Stiasny K, Winkelmann J, Buhlinger A, Brandenburg U, Penzel T et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999; 52(5):944-50.  [ABSTRACT]
  53. Earley CJ, Yaffee JB, Allen RP. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 1998; 51(6):1599-602.
  54. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988; 24(3):455-8.
  55. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363(9416):1179-83.
  56. Danoff SK, Grasso ME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001; 120(1):313-6.
  57. Gispen-de Wied C, Van der Giesen WF. Pergolide alleen voor tweedelijnsbehandeling. Geneesmiddelenbulletin 2005; 39(6):72.
  58. Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004; 27(5):907-14.
  59. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004; 19(12):1414-23.
  60. Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, De Weerd AW, Tidswell P et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004; 75(1):92-97.
  61. Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998; 73(6):497-500.
  62. Becker PM, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998; 51(4):1221-3.
  63. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000; 7 Suppl 1:27-31.
  64. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999; 52(5):938-43.  [ABSTRACT]
  65. Garcia-Borreguero D, Larrosa O, De La LY, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology 2002; 59(10):1573-9.  [ABSTRACT]
  66. Zucconi M, Coccagna G, Petronelli R, Gerardi R, Mondini S, Cirignotta F. Nocturnal myoclonus in restless legs syndrome effect of carbamazepine treatment. Funct Neurol 1989; 4(3):263-71.
  67. Mitler MM, Browman CP, Menn SJ, Gujavarty K, Timms RM. Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam. Sleep 1986; 9(3):385-92.
  68. Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlami A et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 2001; 11(2):153-61.
  69. Walters AS, Hening W. Clinical presentation and neuropharmacology of restless legs syndrome. Clin Neuropharmacol 1987; 10(3):225-37.
  70. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16(4):327-32.
  71. Schapira AH. Restless legs syndrome: an update on treatment options. Drugs 2004; 64(2):149-58.
  72. Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the Treatment of Patients With Restless Legs Syndrome: A US-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Mayo Clin Proc 2006; 81(1):17-7.
  73. Giorgi L, Ritchie SY, Kirsch JM. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total scor 24 points - data from the ropinirole clinical trial programme. Mov Disord 2006; 22(10):1867-7.
  74. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics 1999; 15(2):141-55.
  75. Tompson D, Della Pasqua O. A single-blind, placebo-controlled, forced-titration study of ropinirole in RLS: pharmacokinetic-pharmacodynamic relationships. Sleep 27[abstract suppl]. 2004.
  76. Prevalentie en impact van het restles legs syndroom in de huisartenpraktijk. M.Baggen, M.Timmermans, A. de Weerd. Huisarts en Wetenschap 2007;50(4)136-193.
  77. Aramideh M, Weerd AW de. Het 'restless legs'-syndroom, te behandelen met dopamineagonisten. Ned Tijdschr Geneeskd 2006; 150; 2173-7.
  78. Dijk JG van, Bollen ELEM, Slootweg J, Meer CM van der, Durian FW en Zwinderman AH. Geen verschil in werkzaamheid tussen hydrokinine en placebo bij het 'restless legs'-syndroom. Ned Tijdschr Geneeskd 1991;135;759-63.


 Conclusie